{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:53:21Z","timestamp":1793836401141,"version":"4.6.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Key Technology Research and Developmental Program of China","award":["2022YFC2704401"],"award-info":[{"award-number":["2022YFC2704401"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14481-6","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T07:16:30Z","timestamp":1751354190000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Metabolic syndrome combined with insulin resistance showed great predictive value in evaluating recurrence in patients with atypical endometrial hyperplasia and early endometrial cancer"],"prefix":"10.1186","volume":"25","author":[{"given":"Yuman","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianliu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingchen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"issue":"10333","key":"14481_CR1","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/S0140-6736(22)00323-3","volume":"399","author":"EJ Crosbie","year":"2022","unstructured":"Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. Lancet. 2022;399(10333):1412\u201328.","journal-title":"Lancet"},{"issue":"4","key":"14481_CR2","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/jnci\/djx214","volume":"110","author":"J Lortet-Tieulent","year":"2018","unstructured":"Lortet-Tieulent J, Ferlay J, Bray F, Jemal A. International patterns and trends in endometrial Cancer incidence, 1978\u20132013. J Natl Cancer Inst. 2018;110(4):354\u201361.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"14481_CR3","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.jmig.2017.07.022","volume":"25","author":"C Corzo","year":"2018","unstructured":"Corzo C, Barrientos Santillan N, Westin SN, Ramirez PT. Updates on Conservative management of endometrial Cancer. J Minim Invasive Gynecol. 2018;25(2):308\u201313.","journal-title":"J Minim Invasive Gynecol"},{"issue":"1","key":"14481_CR4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1097\/AOG.0000000000002390","volume":"131","author":"N Pal","year":"2018","unstructured":"Pal N, Broaddus RR, Urbauer DL, Balakrishnan N, Milbourne A, Schmeler KM, Meyer LA, Soliman PT, Lu KH, Ramirez PT, et al. Treatment of Low-Risk endometrial Cancer and complex atypical hyperplasia with the Levonorgestrel-Releasing intrauterine device. Obstet Gynecol. 2018;131(1):109\u201316.","journal-title":"Obstet Gynecol"},{"issue":"3","key":"14481_CR5","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.fertnstert.2013.11.028","volume":"101","author":"M Koskas","year":"2014","unstructured":"Koskas M, Uzan J, Luton D, Rouzier R, Darai E. Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: systematic review and meta-analysis. Fertil Steril. 2014;101(3):785\u201394.","journal-title":"Fertil Steril"},{"issue":"3","key":"14481_CR6","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1159\/000443743","volume":"68","author":"M Uzunlulu","year":"2016","unstructured":"Uzunlulu M, Telci Caklili O, Oguz A. Association between metabolic syndrome and Cancer. Ann Nutr Metab. 2016;68(3):173\u20139.","journal-title":"Ann Nutr Metab"},{"issue":"6","key":"14481_CR7","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1097\/MOU.0000000000001041","volume":"32","author":"F Belladelli","year":"2022","unstructured":"Belladelli F, Montorsi F, Martini A. Metabolic syndrome, obesity and cancer risk. Curr Opin Urol. 2022;32(6):594\u20137.","journal-title":"Curr Opin Urol"},{"issue":"3","key":"14481_CR8","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.rbmo.2021.06.007","volume":"43","author":"M Vaugon","year":"2021","unstructured":"Vaugon M, Peigne M, Phelippeau J, Gonthier C, Koskas M. IVF impact on the risk of recurrence of endometrial adenocarcinoma after fertility-sparing management. Reprod Biomed Online. 2021;43(3):495\u2013502.","journal-title":"Reprod Biomed Online"},{"issue":"4","key":"14481_CR9","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1158\/1940-6207.CAPR-19-0399","volume":"13","author":"J Yin","year":"2020","unstructured":"Yin J, Ma S, Shan Y, Wang Y, Li Y, Jin Y, Pan L. Risk factors for recurrence in patients with atypical endometrial hyperplasia and endometrioid adenocarcinoma after Fertility-Sparing treatments. Cancer Prev Res (Phila). 2020;13(4):403\u201310.","journal-title":"Cancer Prev Res (Phila)"},{"issue":"7","key":"14481_CR10","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.7150\/jca.23631","volume":"9","author":"H Sha","year":"2018","unstructured":"Sha H, Hu D, Wu S, Peng F, Xu G, Fan G, Lin X, Chen G, Liang B, Chen Y, et al. Baseline metabolic risk score and postsurgical esophageal Cancer-Specific mortality: the Fujian prospective investigation of Cancer (FIESTA) study. J Cancer. 2018;9(7):1173\u201381.","journal-title":"J Cancer"},{"issue":"3","key":"14481_CR11","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.ygyno.2014.01.004","volume":"132","author":"W Shan","year":"2014","unstructured":"Shan W, Ning C, Luo X, Zhou Q, Gu C, Zhang Z, Chen X. Hyperinsulinemia is associated with endometrial hyperplasia and disordered proliferative endometrium: a prospective cross-sectional study. Gynecol Oncol. 2014;132(3):606\u201310.","journal-title":"Gynecol Oncol"},{"key":"14481_CR12","doi-asserted-by":"crossref","unstructured":"Li X, Wang Y, Wang J, Zhou J, Wang J. Diagnostic significance and predictive efficiency of metabolic risk score for fertility-sparing treatment in patients with atypical endometrial hyperplasia and early endometrial carcinoma. J Gynecol Oncol 2024.","DOI":"10.3802\/jgo.2024.35.e42"},{"key":"14481_CR13","doi-asserted-by":"publisher","first-page":"6803","DOI":"10.2147\/CMAR.S188087","volume":"10","author":"Y Wang","year":"2018","unstructured":"Wang Y, Yang JX. Fertility-preserving treatment in women with early endometrial cancer: the Chinese experience. Cancer Manag Res. 2018;10:6803\u201313.","journal-title":"Cancer Manag Res"},{"key":"14481_CR14","doi-asserted-by":"publisher","first-page":"744689","DOI":"10.3389\/fonc.2021.744689","volume":"11","author":"X Li","year":"2021","unstructured":"Li X, Fan Y, Wang J, Zhou R, Tian L, Wang Y, Wang J. Insulin resistance and metabolic syndrome increase the risk of relapse for fertility preserving treatment in atypical endometrial hyperplasia and early endometrial Cancer patients. Front Oncol. 2021;11:744689.","journal-title":"Front Oncol"},{"issue":"2","key":"14481_CR15","doi-asserted-by":"publisher","first-page":"217","DOI":"10.6004\/jnccn.2022.7254","volume":"21","author":"S Gordhandas","year":"2023","unstructured":"Gordhandas S, Zammarrelli WA, Rios-Doria EV, Green AK, Makker V. Current Evidence-Based systemic therapy for advanced and recurrent endometrial Cancer. J Natl Compr Canc Netw. 2023;21(2):217\u201326.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"14481_CR16","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6.","journal-title":"Nat Rev Dis Primers"},{"key":"14481_CR17","doi-asserted-by":"publisher","first-page":"780769","DOI":"10.3389\/fendo.2021.780769","volume":"12","author":"X Yang","year":"2021","unstructured":"Yang X, Li X, Dong Y, Fan Y, Cheng Y, Zhai L, Zhang S, Zhou J, Wang J. Effects of metabolic syndrome and its components on the prognosis of endometrial Cancer. Front Endocrinol (Lausanne). 2021;12:780769.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"14481_CR18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12967-023-04671-w","volume":"22","author":"X Li","year":"2024","unstructured":"Li X, Wang Y, Wang J, Fan Y, Wang J. Prediction of complete regression in fertility-sparing patients with endometrial cancer and apical hyperplasia: the GLOBAL model in a large Chinese cohort. J Transl Med. 2024;22(1):127.","journal-title":"J Transl Med"},{"issue":"1","key":"14481_CR19","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12958-022-01006-0","volume":"20","author":"Y Ding","year":"2022","unstructured":"Ding Y, Fan Y, Li X, Wang Y, Wang J, Tian L. Metabolic syndrome is an independent risk factor for time to complete remission of fertility-sparing treatment in atypical endometrial hyperplasia and early endometrial carcinoma patients. Reprod Biol Endocrinol. 2022;20(1):134.","journal-title":"Reprod Biol Endocrinol"},{"issue":"1","key":"14481_CR20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ogc.2018.09.006","volume":"46","author":"ME McDonald","year":"2019","unstructured":"McDonald ME, Bender DP. Endometrial cancer: obesity, genetics, and targeted agents. Obstet Gynecol Clin North Am. 2019;46(1):89\u2013105.","journal-title":"Obstet Gynecol Clin North Am"},{"issue":"2","key":"14481_CR21","first-page":"CD012513","volume":"2","author":"S Kitson","year":"2018","unstructured":"Kitson S, Ryan N, MacKintosh ML, Edmondson R, Duffy JM, Crosbie EJ. Interventions for weight reduction in obesity to improve survival in women with endometrial cancer. Cochrane Database Syst Rev. 2018;2(2):CD012513.","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"14481_CR22","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1210\/en.2014-1072","volume":"155","author":"R Simo","year":"2014","unstructured":"Simo R, Saez-Lopez C, Lecube A, Hernandez C, Fort JM, Selva DM. Adiponectin upregulates SHBG production: molecular mechanisms and potential implications. Endocrinology. 2014;155(8):2820\u201330.","journal-title":"Endocrinology"},{"issue":"18","key":"14481_CR23","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1016\/j.ejca.2015.08.031","volume":"51","author":"AV Hernandez","year":"2015","unstructured":"Hernandez AV, Pasupuleti V, Benites-Zapata VA, Thota P, Deshpande A, Perez-Lopez FR. Insulin resistance and endometrial cancer risk: A systematic review and meta-analysis. Eur J Cancer. 2015;51(18):2747\u201358.","journal-title":"Eur J Cancer"},{"issue":"6","key":"14481_CR24","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s10552-016-0751-4","volume":"27","author":"MA Merritt","year":"2016","unstructured":"Merritt MA, Strickler HD, Einstein MH, Yang HP, Sherman ME, Wentzensen N, Brouwer-Visser J, Cossio MJ, Whitney KD, Yu H, et al. Insulin\/IGF and sex hormone axes in human endometrium and associations with endometrial cancer risk factors. Cancer Causes Control. 2016;27(6):737\u201348.","journal-title":"Cancer Causes Control"},{"issue":"3","key":"14481_CR25","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.ygyno.2012.03.032","volume":"125","author":"N Mu","year":"2012","unstructured":"Mu N, Zhu Y, Wang Y, Zhang H, Xue F. Insulin resistance: a significant risk factor of endometrial cancer. Gynecol Oncol. 2012;125(3):751\u20137.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"14481_CR26","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.3802\/jgo.2018.29.e35","volume":"29","author":"B Yang","year":"2018","unstructured":"Yang B, Xie L, Zhang H, Zhu Q, Du Y, Luo X, Chen X. Insulin resistance and overweight prolonged fertility-sparing treatment duration in endometrial atypical hyperplasia patients. J Gynecol Oncol. 2018;29(3):e35.","journal-title":"J Gynecol Oncol"},{"issue":"3","key":"14481_CR27","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.ygyno.2022.04.008","volume":"165","author":"X Ma","year":"2022","unstructured":"Ma X, Ren X, Ma F, Cai S, Ning C, Liu J, Chen X, Zhang G, Qiang J. Volumetric apparent diffusion coefficient (ADC) histogram metrics as imaging biomarkers for pretreatment predicting response to fertility-sparing treatment in patients with endometrial cancer. Gynecol Oncol. 2022;165(3):594\u2013602.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"14481_CR28","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1186\/s13063-024-08414-0","volume":"25","author":"Q Liu","year":"2024","unstructured":"Liu Q, Zhou H, Yu M, Cao D, Yang J. GnRH-a-based fertility-sparing treatment of atypical endometrial hyperplasia (AEH) and early endometrial carcinoma (EC) patients: a multicenter, open-label, randomized designed clinical trial protocol. Trials. 2024;25(1):578.","journal-title":"Trials"},{"key":"14481_CR29","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ygyno.2023.11.006","volume":"179","author":"C Dagher","year":"2023","unstructured":"Dagher C, Manning-Geist B, Ellenson LH, Weigelt B, Rios-Doria E, Barry D, Abu-Rustum NR, Leitao MM Jr., Mueller JJ. Molecular subtyping in endometrial cancer: A promising strategy to guide fertility preservation. Gynecol Oncol. 2023;179:180\u20137.","journal-title":"Gynecol Oncol"},{"key":"14481_CR30","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ygyno.2024.04.013","volume":"186","author":"H Peng","year":"2024","unstructured":"Peng H, Jiang J, Li L, Hao Z, Lian H, Du H, Wang W. Mismatch repair deficiency and abnormal p53 expression has significant predictive value for progesterone resistance and endometrial tumorigenesis in patients with endometrial atypical hyperplasia receiving fertility-preserving treatment. Gynecol Oncol. 2024;186:154\u201360.","journal-title":"Gynecol Oncol"},{"key":"14481_CR31","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ygyno.2024.10.022","volume":"192","author":"MA Powell","year":"2025","unstructured":"Powell MA, Cibula D, O\u2019Malley DM, Boere I, Shahin MS, Savarese A, Chase DM, Gilbert L, Black D, Herrstedt J, et al. Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR\/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO\/GOG-3031\/RUBY). Gynecol Oncol. 2025;192:40\u20139.","journal-title":"Gynecol Oncol"},{"key":"14481_CR32","doi-asserted-by":"crossref","unstructured":"Islam MS, Afrin S, Jones SI, Segars J. Selective progesterone receptor Modulators-Mechanisms and therapeutic utility. Endocr Rev 2020, 41(5).","DOI":"10.1210\/endrev\/bnaa012"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14481-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14481-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14481-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T19:04:16Z","timestamp":1751396656000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14481-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14481"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14481-6","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"9 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval of the research protocol is by the Ethics Committees of Peking University People\u2019s Hospital (Approval No. 2022PHB-001).Human ethics and consent to participate was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1094"}}